# A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom

> **NCT04583995** · PHASE3 · COMPLETED · sponsor: **Novavax** · enrollment: 15185 (actual)

## Conditions studied

- SARS-CoV-2 Infection
- COVID-19

## Interventions

- **BIOLOGICAL:** SARS-CoV-2 rS/Matrix M1-Adjuvant
- **OTHER:** Placebo
- **BIOLOGICAL:** Licensed seasonal influenza vaccine

## Key facts

- **NCT ID:** NCT04583995
- **Lead sponsor:** Novavax
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-28
- **Primary completion:** 2022-03-29
- **Final completion:** 2022-03-29
- **Target enrollment:** 15185 (ACTUAL)
- **Last updated:** 2025-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04583995

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04583995, "A Study Looking at the Effectiveness, Immune Response, and Safety of a COVID-19 Vaccine in Adults in the United Kingdom". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04583995. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*